RECRUITING

Triage Survey for Infectious Disease Eligibility

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

SWIFT-ID-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials for diagnosis, treatment, or prevention of infectious diseases such as in the areas of HIV, vaccines, and other infectious-diseases areas. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical/surgical history, physical examination, comorbidities, and any current symptoms. Informed consent will be done electronically (preferable) or on paper. Informed consent may be done in-person or remotely, depending on patient preference. Information related to HIV, hepatitis B and C, other infectious diseases, or substance use disorder will also be obtained if applicable. Site staff may collect vital signs, fingerpick testing, urine drug screens, blood draws, EKG, and pregnancy tests. Some testing may be recommended in a fasting condition. A doctor will review medical history and results of the above evaluations with the participant to determine study suitability via clinical interview. The doctor may reach out to the patient's current treating physicians, other providers, and pharmacies to determine eligibility for clinical trials. A follow-up phone call may be needed to discuss testing results and/or trial eligibility. If a participant is deemed eligible for future trials and if the participant remains interested, counseling on contraception requirements for trials will be discussed.

Official Title

Triage Survey for Infectious Disease Eligibility (SWIFT-ID-101)

Quick Facts

Study Start:2024-06-28
Study Completion:2029-01-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06492187

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 2. Participant is at least 18 years old.
  1. 1. Participants are pregnant, breast-feeding, or planning to become pregnant.
  2. 2. History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results or makes them unsuitable for the study for another reason.
  3. 3. Current or recent moderate or severe substance use disorder impacting their ability to follow study related procedures.
  4. 4. Reported history of coagulopathy or bleeding disorder considered a contraindication to phlebotomy.
  5. 5. Any condition that in the investigator's opinion makes a participant unsuitable for the clinical trial study.
  6. 6. Currently employed by Swift Clinical Research Group, Inc. or any of its subsidiaries, including Brooklyn Clinical Research, or a first-degree relative of an employee.

Contacts and Locations

Study Contact

Ammara Mushtaq, MD
CONTACT
9292035879
amushtaq@brooklynclinicalresearch.com
Katherine Azer, MS
CONTACT
9293327848
kazer@brooklynclinicalresearch.com

Study Locations (Sites)

Brooklyn Clinical Research
Brooklyn, New York, 11226
United States

Collaborators and Investigators

Sponsor: Brooklyn Clinical Research

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-28
Study Completion Date2029-01-28

Study Record Updates

Study Start Date2024-06-28
Study Completion Date2029-01-28

Terms related to this study

Additional Relevant MeSH Terms

  • Vaccination; Infection
  • HIV-1-infection
  • Infectious Disease